Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901260 · ClinicalTrials.gov registry record
AMAZE™ Asthma Implementation QI Study
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 117
- Enrollment target
NCT04901260: Completed study, sponsored by AstraZeneca.
NCT04901260 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 117 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04901260 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 117 participants
- Enrollment target
Study Summary
The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.
Primary Outcome
Patient app usage will be measured as the number of days the patient engages (i.e., completes daily log, sends a message) with the app at least once a day during the study period.
Interventions
- DEVICE AMAZE™ Disease Management Platform
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2020-11-25 |
| Est. Completion | 2021-06-30 |
What the finished NCT04901260 record still lists
NCT04901260 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which AMAZE™ Disease Management Platform is the first listed.
NCT04901260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04901260 about?
NCT04901260 is a clinical study titled "AMAZE™ Asthma Implementation QI Study". The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.
What is the current status of trial NCT04901260?
This trial is currently completed. The enrollment target is 117 participants. The study started on 2020-11-25. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04901260?
The interventions under investigation include: AMAZE™ Disease Management Platform (DEVICE).
Who is sponsoring clinical trial NCT04901260?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI